These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

923 related items for PubMed ID: 8866556

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [Abstract] [Full Text] [Related]

  • 4. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.
    Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

  • 6. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL, Holst JJ, Vølund A, Madsbad S.
    Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S.
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC.
    Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. GLP-1 does not not acutely affect insulin sensitivity in healthy man.
    Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O.
    Diabetologia; 1996 Oct; 39(10):1227-32. PubMed ID: 8897012
    [Abstract] [Full Text] [Related]

  • 15. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [Abstract] [Full Text] [Related]

  • 16. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Regul Pept; 2003 Jul 15; 114(2-3):115-21. PubMed ID: 12832099
    [Abstract] [Full Text] [Related]

  • 17. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.
    Diabet Med; 1998 Nov 15; 15(11):937-45. PubMed ID: 9827848
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
    J Clin Invest; 1993 Jan 15; 91(1):301-7. PubMed ID: 8423228
    [Abstract] [Full Text] [Related]

  • 20. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
    Ahrén B, Larsson H, Holst JJ.
    J Clin Endocrinol Metab; 1997 Feb 15; 82(2):473-8. PubMed ID: 9024239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.